EN | UA
EN | UA

Help Support

Back

Glecaprevir/pibrentasvir therapy is effective and well-tolerated in people with hepatitis

Glecaprevir/pibrentasvir therapy is effective and well-tolerated in people with hepatitis Glecaprevir/pibrentasvir therapy is effective and well-tolerated in people with hepatitis
Glecaprevir/pibrentasvir therapy is effective and well-tolerated in people with hepatitis Glecaprevir/pibrentasvir therapy is effective and well-tolerated in people with hepatitis

What's new?

In patients suffering from hepatitis C virus infection, treatment with glecaprevir/pibrentasvir was effective with a good tolerability profile.

An integrated assessment of five phase II and III trials revealed high efficacy and tolerability of glecaprevir/pibrentasvir combination therapy for eight weeks or twelve weeks in individuals with hepatitis C virus infection with or without compensated cirrhosis, with most people attaining sustained virologic response at twelve weeks (SVR12). The safety profile was comparable to that noted in a pooled assessment of a global pan-genotypic population of people with hepatitis C virus infection who received glecaprevir/pibrentasvir.

Jeong Heo et al. undertook the study to examine safety and efficacy of glecaprevir/pibrentasvir  (pan-genotypic direct-acting antiviral combination therapy) for chronic hepatitis C virus infection. The study researchers evaluated pooled data on people having hepatitis C virus infection that were recruited in VOYAGE I and II, ENDURANCE 1 and 2, SURVEYOR II part 4 trials. These trials investigated the safety and efficacy of eight or twelve weeks of glecaprevir/pibrentasvir therapy.

Participants were either therapy-naïve or had received sofosbuvir or interferon-based therapy. Efficacy was assessed by determining the rate of SVR12 posttreatment. By monitoring noxious events and lab evaluations, determination of safety was done. A total of 265 participants were incorporated into the study. Notably, 179 (67.5%) participants were hepatitis C virus treatment-naïve, and the majority of the participants were either subgenotype 2A (44.5%) or 1B (48.7%). SVR12 was attained by 262 (98.9%) participants in the intention-to-treat population.

In total, 3 participants did not attain SVR12: 2 had non-virologic failures and 1 had virologic failure. The majority of the noxious events were grade 1/2; 8 participants (3.0%) had at least 1 grade ≥3 adverse events. There were no severe side effects associated with glecaprevir/pibrentasvir therapy, and grade ≥3 hepatic lab abnormalities were rare (0.8%).

Source:

Gut Liver

Article:

Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials

Authors:

Jeong Heo et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru
Try: